Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry

Shiiba, Michiyo; Zhang, Bo; Miura, Shin‐ichiro; Ike, Amane; Nose, Daisuke; Kuwano, Takashi; Imaizumi, Satoshi; Sugihara, Makoto; Iwata, Atsushi; Nishikawa, Hiroaki; Kawamura, Akira; Shirai, Kohji; Yasunaga, Shin’ichiro; Saku, Keijiro

doi:10.1007/s00380-017-1036-x

Cited by 11 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, high level of non-HDL-c/TC, but not non-HDL-c, showed poor outcomes in 1-year follow-up. Our findings are similar to previously published studies [25, 26]. In those studies, statin might be one of the major confounding factors which could affect the non-HDL-c level.…”

Section: Discussionsupporting

confidence: 92%

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes

Huang

Wei

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

Background. Non-high-density lipoprotein cholesterol (non-HDL-c) predicts the severity of coronary artery lesions in patients not treated with statin. The association between non-HDL-c and severity of coronary artery lesions in patients treated with lipid-lowering therapy has been unknown. Hypothesis. We hypothesize a novel marker of non-HDL-c/TC predicts the severity of coronary artery lesions and clinical outcomes in 12 months in the patients treated with statin. Method. 473 subjects who met inclusion criteria were eligible for inclusion. Coronary artery angiography (CAG) was performed, and the Gensini score (GS) was calculated in all the subjects divided into three subgroups of low risk, medium risk, and high risk by the tertiles of GS. The non-HDL-c value was calculated as TC minus HDL-c, while non-HDL-c/TC was the ratio of non-HDL-c and TC. Results. The concentration of non-LDL-c differed between non-obstructive-CAD group and obstructive-CAD group (P<0.05), and non-HDL-c/TC was elevated in the obstructive-CAD group (P<0.05). Increased GS was associated with increasing non-HDL-c/TC (P<0.05). Non-HDL-c/TC (OR: 108.50, 95% CI: 1.57–7520.28; P=0.030) remained as an independent predicting factor of high risk under GS stratification. In unadjusted Cox model, high non-HDL-c/TC (RR: 1.976, 95% CI: 1.155–3.382; P=0.013) predicted the occurrence of adverse events. After multivariate adjustment, high non-HDL-c/TC (RR: 1.921, 95% CI: 1.105–3.339; P=0.021) was an independent predictor of poor outcomes. Conclusion. High level of non-HDL-c/TC presented an excellent prognostic value compared with other lipid-related markers in CAD patients treated with statin.

show abstract

Section: Discussionsupporting

confidence: 92%

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes

Huang

Wei

et al. 2019

Cardiology Research and Practice

View full text Add to dashboard Cite

show abstract

“…This TZD also significantly increased triglyceride levels in 50 patients who were given at 4 mg/day for 3 months in addition to their usual treatment compared to baseline levels [86,87]. Higher LDL-C level was consistently and independently associated with higher incidences of major adverse cardiovascular events after controlling for conventional risk factors [88]. Third, overload of intravascular volume.…”

Section: Tzds Increase Risks Of Myocardial Infarctionmentioning

confidence: 82%

Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism

Jiang¹,

Balschi²,

McGowan³

et al. 2018

Cardiotoxicity

View full text Add to dashboard Cite

Thiazolidinediones (TZDs), peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are highly effective antidiabetic drugs that are widely used to treat type 2 diabetes mellitus (T2DM) due to their unique beneficial actions, such as a renoprotective effect, amelioration of glucose homeostasis, and blood pressure lowering, that other antidiabetic drugs do not have. Those beneficial actions, however, are shadowed by the increased risks of cardiovascular adverse events, including mitochondrial dysfunction, oxidative stress and myocardial energy deficiency, fluid retention, congestive heart failure, and myocardial infarction. Except PPARγ, TZDs also have affinity to numerous non-PPARγ targets in mitochondria, cytosol, and cytoplasm, including MitoNEET, mitochondrial pyruvate carrier, dehydrogenases involved in tricarboxylic acid cycle and electron transport, cytoplasmic ion channels, Na-K-pump, and other unknown enzymes. By binding to these targets, TZDs produce off-target effects and potentially increase cardiotoxicity. In this chapter, we review recent studies, both experimental and clinical, on the myocardial adverse effects associated with TZDs and their underlying mechanisms. We focus our review in large part on the relationship between these myocardial adverse effects and PPARγ.

show abstract

“…Повышенный уровень ХС ЛНП в сыворотке крови является доказанным фактором риска развития сердечно-сосудистых заболеваний, обусловленных атеросклеротическим процессом, и их последующего прогрессирования [36]. Снижение уровня ХС ЛНП ассоциируется с улучшением прогноза у пациентов после перенесенного коронарного стентирования, однако даже при достижении целевых уровней ХС ЛНП возможные риски сохраняются.…”

Section: оригинальные статьи §unclassified

The Incidence and Possible Predictors of Coronary Restenosis

et al. 2020

View full text Add to dashboard Cite

Objective. Assess time and possible predictors of restenosis after the implantation of first- and second-generation coronary stents and bare metal stents (BMSs) in patients with stable coronary artery disease after elective coronary stenting.Materials and Methods. From 2010 to 2014, 3,732 (2,897 males, 60 [53; 68] years old) patients with stable exertional angina of functional class I–III underwent coronary stenting. From 2014 to 2017, 1,487 (1,173 males and 314 females) patients returned. Repeat coronary angiography was performed in 699 patients.Results. A total of 644 first-generation stents, 5,321 second-generation stents, and 473 BMSs were implanted. During the control coronary angiography, contrasting was repeated for 193 first-generation stents, 899 second-generation stents, and 77 BMSs. Restenosis (stenosis of 50 % or more in the previously stented segment) was detected in 28 (14 % of angiographic control) first-generation drug-eluting stents, 94 (10 %) second-generation drug-eluting stents, and 21 (27 %) BMSs. Patients with BMS restenosis returned significantly earlier than patients with restenosis of the first- and second-generation drug-eluting stents (11 [6, 27] months vs. 32 [11; 48]) months and 24 [12; 42] months, respectively; p<0.05). The initial and repeat levels of high-sensitivity C-reactive protein (hs-CRP) were higher in patients with restenosis (2.2 [1.2, 5.0] mg / L vs. 2.1 [1.0, 4.6] mg / L, respectively; p> 0.05) than in patients without restenosis (2.0 [0.9, 4.2] mg / L vs. 1.9 [0.7, 3.5] mg / L respectively, p>0.05). Blood levels of hs-CRP ≥2 mg / L according to receiver operating characteristic curve (ROC) analysis at return visit were used as a predictor to identify restenosis of stents with a diameter <3 mm and a length >25 mm – area under the curve (AUC) 0.67 (95 % confidence interval (CI) 0.51–0.84), p <0.05, odds ratio 3.7 (95 % CI 1.1–12.1), p<0.05. Stent type had a significant effect on the time to restenosis in the survival analysis (p<0.0005).Conclusion. The time from coronary stenting to the return visit of patients presenting with restenosis after the implantation of first- and second-generation drug-eluting stents is consistent; median time of the return visit of patients with restenosis of the first-generation stents was 2–3 years after coronary stenting. Blood levels of hs-CRP ≥2 mg / L at the return visit is a predictor of restenosis of stents with a diameter <3 mm and a length >25 mm.

show abstract

Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry

Cited by 11 publications

References 28 publications

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes

Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism

The Incidence and Possible Predictors of Coronary Restenosis

Contact Info

Product

Resources

About